14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SGP vs DNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SGP Captures Overall Composite Edge (39.3 SELL vs 57.4 HOLD), While DNA Leads 3–2 on Growth & Valuation Pillars
SGP Overall Winner
6-Pillar Tally: SGP 2 – 3 DNA (1 Tie)
Matrix Metrics: SGP 2 – 6 DNA
As of Nov 16, 2026, SGP (SGP) captures the overall head-to-head institutional edge over Ginkgo Bioworks Holdings, Inc. (DNA) on higher Unified Composite conviction (39.3/100 SELL vs. 57.4/100 HOLD) after splitting the core matrix 2–6 (led by Balance Sheet & Cash Flow, Options & Positioning), while DNA wins 3–2 across the 6-pillar growth and valuation breakdown. SGP trades at $32.24 (N/M Forward P/E, N/A operating margin) versus DNA at $8.50 (N/M Forward P/E, -202.5% operating margin).
Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (57.4/100 HOLD vs. SGP 39.3/100 SELL), SGP captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. -202.5% operating margin) and revenue trajectory (N/A vs. -5.7% YoY).
Technical & Structure Timing Caution: SGP trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.7); meanwhile DNA is in a Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGP vs DNA. Trailing 12-month operating profitability (SGP N/A vs DNA -202.5%) and valuation multiples (SGP N/M vs DNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
DNA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $623.0M market capitalization and -202.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SGP vs DNA Key Questions & Quantitative Answers
As of Nov 16, 2026, SGP (SGP) captures the overall head-to-head institutional edge over Ginkgo Bioworks Holdings, Inc. (DNA) on higher Unified Composite conviction (39.3/100 SELL vs. 57.4/100 HOLD) after splitting the core matrix 2–6 (led by Balance Sheet & Cash Flow, Options & Positioning), while DNA wins 3–2 across the 6-pillar growth and valuation breakdown. SGP trades at $32.24 (N/M Forward P/E, N/A operating margin) versus DNA at $8.50 (N/M Forward P/E, -202.5% operating margin). Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (57.4/100 HOLD vs. SGP 39.3/100 SELL), SGP captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. -202.5% operating margin) and revenue trajectory (N/A vs. -5.7% YoY). Technical & Structure Timing Caution: SGP trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.7); meanwhile DNA is in a Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DNA leads the Growth & Scale pillar: SGP posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with DNA at -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin). On trailing 12-month operating scale, SGP generates N/A in USD-normalized revenue versus $131M for DNA. In operating R&D and SG&A reinvestment, SGP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNA.
DNA screens cheaper on headline valuation multiples. SGP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGP (N/A ROE) versus DNA (-58.2% ROE) capital efficiency.
In options market volatility and institutional positioning, SGP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 70% Vol realized risk). By comparison, DNA carries 119.2% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.14β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.